Rockwell Medical is a biopharmaceutical company that focuses on developing and providing innovative treatments for patients with chronic kidney disease and end-stage renal disease
The company specializes in therapies aimed at addressing the complications associated with these conditions, particularly iron deficiency anemia. Rockwell Medical is engaged in the research and development of solutions that enhance the quality of life for patients undergoing dialysis and other renal care, aiming to improve patient outcomes through effective medical interventions.
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months and twelve months ended December 31, 2024.
Rockwell Medical, Inc. (the “Company”) (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company will showcase its hemodialysis concentrates portfolio at DialysisTechConneXion42 (“DTX42”). Hosted by the National Association of Nephrology Technicians/Technologists, DTX42 will be held at Planet Hollywood in Las Vegas, Nevada from April 1-4, 2025.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has been certified as a Great Place to Work® for the third year in a row.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2024 on Thursday, March 20, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a distribution services agreement (the "Agreement") with a leading manufacturer of medical equipment including hemodialysis machines, disposable products, and automated fluid balance systems (the "Partner"). Leveraging the Company's existing reliable distribution network and transportation subsidiary, Rockwell Medical will now be able to distribute a single-use bicarbonate cartridge to its customers at dialysis centers, hospital-based outpatient centers, and skilled nursing facilities.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a product purchase agreement (the "Agreement") with the world's leading provider of dialysis products and services ("the Customer").
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Jesse Neri was promoted to Chief Financial Officer.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has partnered with HydroCare, a leading provider of state-of-the-art dialysis water treatment systems to healthcare facilities globally, to purchase and install the Company's dry acid concentrate mix system in dialysis water rooms. Rockwell anticipates that with these new mixer installations through HydroCare, the Company will also generate new sales related to its dry acid hemodialysis concentrates. Rockwell Medical's DAMX45 dry acid concentrate mix system is 510(k) approved to be used exclusively with the Company's CitraPure® and Dri-Sate® dry acid concentrate powders.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a distribution agreement with Nephro Group Dialysis Centers ("Nephro Group"), the largest dialysis provider in the Philippines. Under the terms of the agreement, Rockwell Medical will be the exclusive supplier of all dry hemodialysis concentrates products, including its CitraPure® Acid and RenalPure® Bicarbonate, to Nephro Group.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and nine months ended September 30, 2024.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has updated the date for its third quarter 2024 earnings conference call and webcast and will now release its financial and operational results for the third quarter ended September 30, 2024 on Tuesday, November 12, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the third quarter ended September 30, 2024 on Monday, November 11, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Great Place to Work® and Fortune magazine selected Rockwell Medical for the 2024 Fortune Best Workplaces in Manufacturing and ProductionTM List in the small & medium category.
